Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Post Transplant Cyclophosphamide in Haploidentical HSCT
NCT07719946Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Mar 2025
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Tata Memorial Centre. Started Mar 2025; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07719946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719946.